|Bid||3.8700 x 4000|
|Ask||3.8800 x 2900|
|Day's Range||3.8100 - 4.1000|
|52 Week Range||0.9100 - 4.8000|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sesen Bio Inc (NASDAQ: SESN) participated in a Late-Cycle Meeting with the FDA regarding the marketing application seeking approval for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA confirmed that there is no Advisory Committee meeting planned at this time. No issues related to risk management have been identified to date. No post-marketing requirements, including a confirmatory trial, have been identified as necessary at this time. The Company believes the ap
During Monday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about Sesen Bio : "Take some profits off the table," was Cramer's advice about the company that was formerly Eleven Biotherapeutics. Sesen Bio is a late-stage clinical company that provides a targeted protein therapeutics (TPT) platform. In this daily bar chart of SESN, below, we can see how prices have charged higher the past 12 months.
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.